Ascletis Pharma Inc
HKEX:1672
Intrinsic Value
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. [ Read More ]
The intrinsic value of one
Ascletis Pharma Inc
stock under the Base Case scenario is
0.88
HKD.
Compared to the current market price of 1.38 HKD,
Ascletis Pharma Inc
is
Overvalued by 36%.
Ascletis Pharma Inc's market capitalization is 1.4B HKD.
Ascletis Pharma Inc stock price is 1.38 HKD.
Ascletis Pharma Inc stock (0.88 HKD) is 36% less than its price (1.38 HKD).
Ascletis Pharma Inc. Open DCF Valuation
Ascletis Pharma Inc stock (0.88 HKD) is 36% less than its price (1.38 HKD). Open Relative Valuation
Ascletis Pharma Inc has upside potential of 120% compared to the average analyst price target.
Open Wall St Estimates
Ascletis Pharma Inc's Revenue has grown by 5% over the past 12 months.
Ascletis Pharma Inc's Revenue is forecast to fall at a rate of 1% per year over the next 3 years.
Ascletis Pharma Inc has positive Gross Profit for the last twelve months.
Ascletis Pharma Inc's ROE (Return on Equity) for the past 12 months is negative and is equal to -6%.
Ascletis Pharma Inc has negative Operating Income for the last twelve months.
Ascletis Pharma Inc has negative Net Income for the last twelve months.
Ascletis Pharma Inc's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -167%.
Ascletis Pharma Inc has negative three-year average ROE (Return on Equity): -8%. The company is not efficient at transforming stockholders' equity into net income.
Ascletis Pharma Inc has negative Free Cash Flow for the last twelve months.
Ascletis Pharma Inc's D/E (Debt to Equity) is very low and is equal to 0.
Ascletis Pharma Inc has negative three-year average ROIC (Return on Invested Capital): -106%. The company is not efficient at using invested capital to generate operating income.
Ascletis Pharma Inc's short-term assets (2B CNY) exceed its short-term liabilties (141m CNY).
Ascletis Pharma Inc's long-term assets (2B CNY) exceed its long-term liabilties (149m CNY).
Ascletis Pharma Inc has negative Net Debt. This means that the company has more cash and short-term investments (2B CNY) than debt (3m CNY).
Ascletis Pharma Inc's Altman Z-Score is very high and is equal to 5.42.
Ascletis Pharma Inc doesn't generate enough operating income (-302m CNY) to safely cover interest payments on its debt (144k CNY).
Valuation Backtest
Ascletis Pharma Inc
Run backtest to discover the historical profit from buying and selling
Ascletis Pharma Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ascletis Pharma Inc
Balance Sheet Decomposition
Ascletis Pharma Inc
| Current Assets | 2.3B |
| Cash & Short-Term Investments | 2.3B |
| Receivables | 19.7m |
| Other Current Assets | 13.6m |
| Non-Current Assets | 158.3m |
| Long-Term Investments | 63m |
| PP&E | 68.5m |
| Intangibles | 26.3m |
| Other Non-Current Assets | 376k |
| Current Liabilities | 140.7m |
| Accounts Payable | 649k |
| Other Current Liabilities | 140m |
| Non-Current Liabilities | 8.3m |
| Long-Term Debt | 2.7m |
| Other Non-Current Liabilities | 5.6m |
Earnings Waterfall
Ascletis Pharma Inc
|
Revenue
|
56.6m
CNY
|
|
Cost of Revenue
|
-30.6m
CNY
|
|
Gross Profit
|
26m
CNY
|
|
Operating Expenses
|
-328.2m
CNY
|
|
Operating Income
|
-302.2m
CNY
|
|
Other Expenses
|
157.5m
CNY
|
|
Net Income
|
-144.7m
CNY
|
Free Cash Flow Analysis
Ascletis Pharma Inc
Profitability Score
Profitability Due Diligence
Ascletis Pharma Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Ascletis Pharma Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Ascletis Pharma Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Ascletis Pharma Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Ascletis Pharma Inc
According to Wall Street analysts, the average 1-year price target for
Ascletis Pharma Inc
is 3.04 HKD
with a low forecast of 2.18 HKD and a high forecast of 3.99 HKD.
Shareholder Return
Price
Ascletis Pharma Inc
| Average Annual Return | 1.77% |
| Standard Deviation of Annual Returns | 42.23% |
| Max Drawdown | -81% |
| Market Capitalization | 1.4B HKD |
| Shares Outstanding | 1 012 760 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Ascletis Pharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
Contact
IPO
Employees
Officers
The intrinsic value of one
Ascletis Pharma Inc
stock under the Base Case scenario is
0.88
HKD.
Compared to the current market price of 1.38 HKD,
Ascletis Pharma Inc
is
Overvalued by 36%.
You don't have any saved screeners yet
